^
    CANCER:

    Squamous Cell Carcinoma of Head and Neck





    Show legend
    Group by Gene:
    Include preclinical:

    pembrolizumab
    PD1 inhibitor
    		0
    PD1 inhibitor
    nivolumab
    pembrolizumab + nivolumab
    ABBV-181
    cetuximab
    EGFR inhibitor
    panitumumab
    		1
    EGFR inhibitor
    nimotuzumab
    erlotinib
    cetuximab
    gefitinib
    2
    Thymidylate synthase inhibitor
    5-fluorouracil
    3
    THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
    methotrexate
    4
    DNA synthesis inhibitor
    cisplatin
    5
    PD-L1 inhibitor
    PD-L1 inhibitor
    durvalumab
    6
    PIK3CA inhibitor, CXCL12 inhibitor, Farnesyl transferase inhibitor
    alpelisib + tipifarnib
    7
    HER3 inhibitor, EGFR inhibitor
    cetuximab + ISU104
    8
    IL-2 stimulant
    CUE-101
    9
    PI3K inhibitor
    AN2025
    GDC-0941
    10
    Galectin-9 inhibitor
    LYT-200
    11
    IAP antagonist
    Debio 1143
    12
    APC activator
    eftilagimod alpha
    13
    CLDN1 inhibitor
    ALE.C04
    14
    mTOR inhibitor
    everolimus
    temsirolimus
    15
    Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
    MRG003
    HTI-1511
    16
    ALK inhibitor
    crizotinib
    17
    PIK3CA inhibitor
    alpelisib
    GDC-0032
    pazopanib
    		18
    Multi-tyrosine kinase inhibitor
    nintedanib
    vandetanib
    19
    PD1 inhibitor, EGFR inhibitor
    nivolumab + cetuximab
    cetuximab + toripalimab-tpzi
    20
    CXCL12 inhibitor, Farnesyl transferase inhibitor
    tipifarnib
    21
    FGFR inhibitor
    BAY 1163877
    infigratinib
    22
    WEE1 inhibitor
    AZD1775
    23
    c-MET inhibitor, Hepatocyte growth factor inhibitor, EGFR inhibitor
    cetuximab + AV-299
    24
    SEMA4D inhibitor, PD1 inhibitor
    pembrolizumab + VX15
    25
    PD1 inhibitor, IL-2 stimulant
    pembrolizumab + CUE-101
    26
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    abemaciclib
    27
    PIK3CA inhibitor, EGFR inhibitor
    cetuximab + alpelisib
    28
    PD1 inhibitor, ICOS agonist
    pembrolizumab + GSK3359609
    29
    EGFR-targeted-dye conjugate
    cetuximab sarotalocan
    30
    PD1 inhibitor, PARP inhibitor
    niraparib + dostarlimab-gxly
    31
    PD1 inhibitor, APC activator
    pembrolizumab + eftilagimod alpha
    32
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    TPeX
    		33
    Chemotherapy
    DCF
    TPF
    34
    Immunotherapy
    Immunotherapy
    35
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    afatinib
    36
    PD-L1 inhibitor, CTLA4 inhibitor
    durvalumab + tremelimumab
    37
    Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + docetaxel + 5-fluorouracil
    38
    Tubulin polymerization promoter, Thymidylate synthase inhibitor
    carboplatin + 5-fluorouracil
    39
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + 5-fluorouracil
    40
    HER2 inhibitor, HER4 inhibitor, PD1 inhibitor, EGFR inhibitor
    pembrolizumab + afatinib
    41
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    42
    Immunostimulant, PD1 inhibitor
    pembrolizumab + SNS-301
    GDC-0980
    		43
    PI3K inhibitor, mTOR inhibitor
    RTB101
    GSK2126458
    44
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    45
    HPV-16 E7 protein inhibitor, PD1 inhibitor, HPV-16 E6 protein inhibitor
    pembrolizumab + HB-200
    46
    TGFβ inhibitor, PD1 inhibitor, EGFR inhibitor
    pembrolizumab + BCA101
    47
    HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor
    entinostat
    48
    c-MET inhibitor
    LY2801653
    49
    HDAC inhibitor
    vorinostat
    50
    FGFR inhibitor, mTOR inhibitor, mTORC2 inhibitor
    ABSK091 + AZD2014
    51
    PORCN inhibitor, Wnt signalling pathway inhibitor
    WNT974
    52
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    53
    HSP90 inhibitor
    BMS-722782
    54
    MEK inhibitor
    trametinib
    55
    BET inhibitor
    JQ-1
    56
    Aurora kinase A inhibitor, WEE1 inhibitor
    AZD1775 + VIC-1911
    57
    PI3Kγ inhibitor, PI3Kδ inhibitor
    duvelisib
    58
    PLK1 inhibitor, PI3K inhibitor, RAS antagonist
    rigosertib
    59
    PI3K inhibitor, mTOR inhibitor, mTORC1 inhibitor, mTORC2 inhibitor
    PF-05212384
    60
    mTOR inhibitor, EGFR inhibitor
    cetuximab + AZD8055
    61
    PARP inhibitor
    olaparib
    62
    STAT3 inhibitor, JAK2 inhibitor
    JSI-124
    63
    STAT3 inhibitor
    stattic
    64
    TNKS inhibitor, Wnt signalling pathway inhibitor
    XAV-939
    65
    PI3K inhibitor, mTOR inhibitor, EGFR inhibitor
    cetuximab + RTB101
    66
    EGFR inhibitor, TLR8 agonist
    cetuximab + VTX 2337
    67
    IAP inhibitor
    IGM-9427
    AZD5582
    68
    C4.4a-targeted antibody-drug conjugate, Microtubule inhibitor
    BAY1129980
    69
    B7-H3-targeted antibody-drug conjugate, DNA replication inhibitor
    MGC018
    70
    NK cell stimulant, EGFR inhibitor
    cetuximab + CYNK-101
    71
    HDAC6 inhibitor, WEE1 inhibitor
    AZD1775 + ACY-1215
    72
    PIK3CA inhibitor, CDK4 inhibitor, CDK6 inhibitor
    palbociclib + alpelisib
    73
    DNA PK inhibitor, PARP inhibitor
    olaparib + AZD7648
    No biomarker
    PD-L1 negative
    PD-L1 underexpression
    PD-L1 expression
    PD-L1 overexpression
    TMB-H
    EGFR amplification
    EGFR mutation
    EGFR overexpression
    EGFR expression
    EGFR P753S
    EGFR P546S
    EGFR positive
    EGFR R521K
    EGFRvIII mutation
    PIK3CA mutation
    PIK3CA E542K
    PIK3CA amplification
    PIK3CA Q75E
    PIK3CA E545K
    PIK3CA H1047R
    PIK3CA E110K
    CDKN2A negative
    ERBB3-L
    CDKN2A mutation
    ERBB3 mutation
    CDKN2A R58X
    CLDN1 positive
    ID2 overexpression + TRIM33 overexpression
    PTEN overexpression
    KMT2D mutation
    ATM mutation
    TP53 mutation
    MET overexpression
    MET N375S
    TP53 overexpression
    MET R1004G
    MET elevation
    PTEN expression
    PTEN mutation
    MET positive
    ATM deletion
    HRAS overexpression + PIK3CA amplification
    HRAS overexpression + PIK3CA mutation
    FGFR mutation
    PD-L2 expression
    HRAS mutation
    HRAS overexpression
    TMB-H + PD-L1 overexpression
    PD-L2 overexpression
    FGFR overexpression
    TMB-L + PD-L1 expression
    HRAS A146T
    HRAS Q61L
    HRAS G12S
    HRAS G12D
    HRAS G13R
    HRAS K117N
    HRAS G12C
    PIK3CA mutation + HRAS mutation
    FGFR2 P253R
    PRSS3 underexpression
    TET1 mutation
    NRG1 mutation
    HER-2 mutation
    DDR2 overexpression
    IL1A elevation
    AREG expression
    SMAD4 expression
    FANCI mutation + FLT1 mutation
    FANCA mutation + FGFR3 mutation
    FANCD2 mutation + EP300 mutation
    PIK3CA mutation + EP300 mutation
    IFNG overexpression
    IDO1 overexpression
    IFI35 overexpression
    OASL overexpression
    CXCL9 overexpression
    ABCB1 overexpression
    BCL2 overexpression
    VEGFA overexpression
    DPYD overexpression
    XPA overexpression
    ERCC1 overexpression
    HIF1A overexpression
    IL6 underexpression
    CSF1 underexpression
    CCL23 underexpression
    CD44 underexpression
    HRD
    B2M overexpression
    TERT mutation
    PD-L1 overexpression + CD8 overexpression
    SP140 overexpression
    TNFRSF9 overexpression
    HLA-A*02:01 + PD-L1 expression
    HLA-A*02:01
    CTLA4 promoter hypomethylation
    TERT mutation + TP53 mutation
    CCND1 amplification
    AREG overexpression
    SMAD4 underexpression
    SMAD4 mutation
    SMAD4 deletion
    HER-2 V773A
    Chr amplification(15)(q22.31)
    Choline elevation
    IFNG gene signature
    AXL overexpression
    AXL Y821
    FGFR1 expression
    NOTCH1 mutation
    MAPK1 overexpression
    MTOR overexpression
    NT5E overexpression + PD-L1 expression
    ERBB4 G1109C
    NOTCH1 C478F
    FGFR3 positive
    NOTCH1 C344fs
    NOTCH1 E694
    NOTCH1 G192
    NOTCH1 H2018fs
    NOTCH1 Q1957
    NOTCH1 V489fs
    NOTCH1 E1679
    NOTCH1 A1524V
    NOTCH1 G72R
    NOTCH1 F357del
    LRRC8D underexpression
    FBXW7 mutation
    ETV6-NTRK3 fusion
    FBXW7 deletion
    FGFR1 mutation
    FGFR3 overexpression
    LRRC8A underexpression
    LAG3 expression
    KRT17 overexpression
    MTAP deletion
    MTAP mutation
    FGF2 rs1048201
    PDGFRA rs2228230
    MMP2 rs7201
    TIMP2 rs7501477
    MAPK1 E322K
    PTPRD mutation
    PIK3CD overexpression
    PTPRT promoter methylation
    LAG3 elevation
    FAT1 mutation + FAT1 underexpression
    FAT1 mutation + FAT1 underexpression + CAV1 overexpression
    FAT1 mutation + FAT1 underexpression + IRS1 overexpression
    TLR4 overexpression
    KRAS mutation
    NSD1 mutation
    MAPK1 D321N
    FADD overexpression
    FADD overexpression + BIRC2 overexpression
    FADD amplification
    FADD amplification + BIRC2 amplification
    LYPD3 expression
    CD276 overexpression
    IFIT1 overexpression
    IFIT3 overexpression
    CXCL8 expression
    BIRC2 overexpression + BIRC3 overexpression
    POU5F1 expression
    ROS1 mutation + MSI-L/dMMR
    SMARCA4 mutation + MSI-L/dMMR
    FAT1 mutation
    ARSI overexpression
    BCL2L11 overexpression
    ALDH2 underexpression
    PIK3CG overexpression
    PIK3CG expression
    PIK3CD expression
    MAPK1 R135K
    TLR8 overexpression
    MYC amplification
    MYD88 overexpression